| __timestamp | Lantheus Holdings, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 72429000 | 7751000 |
| Thursday, January 1, 2015 | 78634000 | 10251000 |
| Friday, January 1, 2016 | 75374000 | 9575000 |
| Sunday, January 1, 2017 | 92157000 | 10912000 |
| Monday, January 1, 2018 | 93326000 | 11049000 |
| Tuesday, January 1, 2019 | 103132000 | 11646000 |
| Wednesday, January 1, 2020 | 110171000 | 13265000 |
| Friday, January 1, 2021 | 218817000 | 25805000 |
| Saturday, January 1, 2022 | 233827000 | 35182000 |
| Sunday, January 1, 2023 | 267194000 | 94999000 |
In pursuit of knowledge
In the competitive landscape of the healthcare sector, understanding the financial strategies of key players is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Lantheus Holdings, Inc. and Viridian Therapeutics, Inc. over the past decade.
Lantheus Holdings has shown a significant upward trend in SG&A expenses, with a staggering 270% increase from 2014 to 2023. This growth reflects their aggressive expansion and investment in operational capabilities. In contrast, Viridian Therapeutics, while also increasing their SG&A expenses, has maintained a more conservative growth rate, with a 1,125% rise over the same period, albeit from a much smaller base.
This divergence in financial strategy highlights the differing approaches of these companies in navigating the dynamic healthcare market. Investors and stakeholders should consider these trends when evaluating potential growth and risk factors.
Who Optimizes SG&A Costs Better? Merck & Co., Inc. or Lantheus Holdings, Inc.
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Lantheus Holdings, Inc.
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Corcept Therapeutics Incorporated
Selling, General, and Administrative Costs: Lantheus Holdings, Inc. vs PTC Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Lantheus Holdings, Inc. and Perrigo Company plc
Annual Revenue Comparison: Lantheus Holdings, Inc. vs Viridian Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Lantheus Holdings, Inc. or Taro Pharmaceutical Industries Ltd.
Comparing SG&A Expenses: Lantheus Holdings, Inc. vs Celldex Therapeutics, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of HUTCHMED (China) Limited and Viridian Therapeutics, Inc.